Mark P. Ettinger

TL;DR: In this article, the effect of 10 mg of alendronate or placebo, given daily, on bone mineral density in 241 men with osteoporosis, was studied in a double-blind trial.

TL;DR: In this paper, the safety of recombinant human parathyroid hormone (1-84) and its effect on the incidence of vertebral fractures in postmenopausal women with osteoporosis was investigated.

TL;DR: Sequential treatment of osteoporosis with PTH and alendronate results in an increase in vertebral bone density that is considerably more than has been reported with alendronsate or estrogens alone.

TL;DR: Investigation of the efficacy and safety of human PTH-(1–84) (full-length PTH) in the treatment of postmenopausal osteoporosis in a double-blind, placebo-controlled study found bone turnover markers increased during the first half of the study and were maintained at elevated levels during the second.

TL;DR: In this paper, a double-blind, randomized, parallel-group, dose-ranging, multicenter clinical trial was conducted at 2 university obesity clinics and at 5 independent clinical research clinics from March 2000 to August 2001, and 173 nondiabetic obese adults, 82.6% of whom were women, with a mean (SD) body mass index of 41.1 (4.1).